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Abstract 
Magnetic iron oxide nanoparticles (MIONPs) play a major role in the emerging fields of nanotechnology to facilitate 
rapid advancements in biomedical and industrial platforms. The superparamagnetic properties of MIONPs and their 
environment friendly synthetic methods with well‑defined particle size have become indispensable to obtain their 
full potential in a variety of applications ranging from cellular to diverse areas of biomedical science. Thus, the broad‑
ened scope and need for MIONPs in their demanding fields of applications required to be highlighted for a com‑
prehensive understanding of their state‑of‑the‑art. Many synthetic methods, however, do not entirely abolish their 
undesired cytotoxic effects caused by free radical production and high iron dosage. In addition, the agglomeration of 
MIONPs has also been a major problem. To alleviate these issues, suitable surface modification strategies adaptive to 
MIONPs has been suggested not only for the effective cytotoxicity control but also to minimize their agglomeration. 
The surface modification using inorganic and organic polymeric materials would represent an efficient strategy to 
utilize the diagnostic and therapeutic potentials of MIONPs in various human diseases including cancer. This review 
article elaborates the structural and magnetic properties of MIONPs, specifically magnetite, maghemite and hematite, 
followed by the important synthetic methods that can be exploited for biomedical approaches. The in vivo cytotoxic 
effects and the possible surface modifications employed to eliminate the cytotoxicity thereby enhancing the nano‑
particle efficacy are also critically discussed. The roles and applications of surface modified MIONPs in medical and 
industrial platforms have been described for the benefits of global well‑being.
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Introduction
The specific diverse applications of nanoparticles arise 
from the physical characteristics of the nanomaterials 
they are comprised of. Nanomaterials often reveal novel 
and distinct electrical, optical, magnetic and chemical 
properties as against their bulk materials [1]. Nanoma-
terials are categorized as ‘closely packed materials’ and 
‘nanodispersions’ which include ‘‘nanostructured’’ mate-
rials, i.e., an isotropic material with a macroscopic com-
position consisting of compact nanometre-sized units 
such as the fundamental replicating structural and func-
tional elements [2]. Nanoparticles are pertained to make 
revolutionary technological changes in escalating the 
standards and quality of human health with transforma-
tive and innovative diagnostic, therapeutic and even 
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theranostic tools (that combine the diagnostic and thera-
peutic approaches in a single agent) [3].
Magnetic nanoparticles (MNPs) can be exploited for 
desired applications under the manipulation of an exter-
nal magnetic field. It can be synthesized with a cost effec-
tive and wide spread material like iron as in the case of 
magnetic iron oxide nanoparticles (MIONPs) which is 
least toxic and biodegradable [4–10]. Nanomaterials con-
taining iron are derived from iron nanoalloys, zero valent 
iron and oxides like ferrites, etc. Iron naturally exists in 
the environment as Fe(II) and Fe(III) oxides. Iron oxides 
refer to oxides, hydroxides and oxy-hydroxides contains 
both Fe(II)/Fe(III) cations and  O2−/OH− anions. Sixteen 
pure phases of iron oxides are known till date. These 
includes Fe(OH)2, Fe(OH)3,  Fe3O4,  Fe5HO8.4H2O, FeO, 
four polymorphs of  Fe2O3 and five of FeOOH [11, 12]. 
Characteristics of these oxide compounds are inclusive 
of divalent and trivalent states of the iron, relatively low 
solubility and their brilliant colours. Among the iron 
oxides,  Fe3O4 and γ-Fe2O3 have received wide attention 
and acceptance due to their tunable size-dependent mag-
netic properties [13, 14].
During the last decade, researchers have focused their 
priority towards developing efficient methods for the 
synthesis of MIONPs to address their growing demands 
with desired physical and chemical properties. This 
clearly reflects the increasing need for various synthetic 
approaches to obtain well-crystallized and well-defined 
MIONPs [15, 16]. After synthesis, MIONPs need appro-
priate surface modifications to make them more com-
patible for their respective applications with suitable 
molecular conjugation and functionalization methods 
[17]. Therefore, surface modification becomes a critical 
post-synthetic step for preparing compatible and stable 
MIONPs. A schematic representation that summarizes 
the development of MIONPs is presented in Fig. 1.
At present, MIONPs are widely used in biomedical 
applications such as magnetic bio-separation and detec-
tion of biological entities (for example cells, proteins, 
nucleic acids, enzymes, bacteria, virus, etc.). Further 
MIONPs are implicated in clinical diagnosis like mag-
netic resonance imaging and therapy such as targeted 
drug delivery, magnetic fluid hyperthermia, and biologi-
cal labels for anticancer therapy, catalysis, wastewater 
treatment and oil recovery. The main reasons for the spe-
cific choice of these nanoparticles in such applications are 
due to the controllable size ranging from few nanometers 
to tens of nanometers thereby providing the dimensions 
that are either comparable or closer to those of a protein 
(5–50  nm), a virus (20–450  nm), or even a gene (10–
100 nm long and 2 nm wide). So that it could efficiently 
get into the close vicinity of a biological entity as well as 
the therapeutic target of interest [18]. In addition to that, 
MIONPs can be directed in the presence of an external 
magnetic field gradient, since it obeys Coulomb’s law 
for magnetism. To highlight the industrial demands of 
MIONPs, one needs to understand the exposure of dyes 
and heavy metals in drinking water that causes undesir-
able toxicity to living beings. In recent years, a great deal 
of interest has been developed in using MIONPs for the 
effective removal of dyes and heavy metals during waste-
water treatment [19].
General structural properties of iron oxides
There are eight different iron oxides that are well known 
in nature [20], among them magnetite  (Fe3O4), magh-
emite (γ-Fe2O3) and hematite (α-Fe2O3) shows the unique 
magnetic properties and they have different polymorphic 
forms and undergo temperature induced phase transi-
tion. Magnetite and maghemite are ideal materials for 
industrial and biomedical applications. Both have reus-
able advantage over other iron oxides due to their unique 
magnetic, catalytic and biochemical properties. The 
physical properties of  Fe3O4, γ-Fe2O3 and α-Fe2O3 are 
presented in Table 1 [20–22].
Magnetite
Fe3O4 is derived from various sources such as black iron 
oxide, magnetic iron ore, loadstone, ferrous ferrite and 
Hercules stone.  Fe3O4 has face centered cubic spinel 
structure with both divalent and trivalent iron in it. All of 
the  Fe2+ ions reside in half of the octahedral sites whereas 
the  Fe3+ ions are divided evenly across the remaining 
available octahedral and the tetrahedral sites [20, 21]. It 
reveals strong magnetism when compared to other tran-
sition metal oxides. The saturation magnetization value 
for bulk material is 92 emu/g. It offers a high surface area 
for adsorption and immobilization of molecules or drugs 
for our interest. It can be controlled and easily separated 
by a magnetic field and further applicable for subsequent 
reuse.
Maghemite
γ-Fe2O3 is present in soils as a weathering product of 
 Fe3O4. γ-Fe2O3 has a cubic spinel crystal structure with 
each unit contains 32  O2− and 21½  Fe3+ ions with 2½ 
vacancies. Oxygen anions lead to a cubic close-packed 
arrangement whereas ferric ions are spread over tetra-
hedral and octahedral sites [21, 23]. Since, the atomic 
radii of  Fe3+ ion is smaller than the  Fe2+ ion, the unit cell 
parameter of γ-Fe2O3 is smaller than  Fe3O4. It also shows 
strong magnetism with the saturation magnetization 
value of 78 emu/g for the bulk material.
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Hematite
α-Fe2O3 is the most well-known of the iron oxides and 
is common in rocks and soils namely ferric oxide, iron 
sesquioxide, red ochre, specularite, specular iron ore, 
kidney ore and martite. α-Fe2O3 is blood red in colour, 
and black or grey in crystalline state. In α-Fe2O3, two-
thirds of the octahedral sites are occupied by  Fe3+ ions 
with an ideal hexagonal close-packed oxygen lattice. 
It is extensively used in catalysts, in the preparation 
of pigments and gas sensors due to its cost-effective 
and corrosion resistant. It can also be act as a starting 
material for the synthesis of  Fe3O4 and γ-Fe2O3, which 
extensively used in technological applications during 
recent years [23].
Magnetic properties of iron oxide structures
Iron shows excellent magnetic properties; if we consider 
it as a single atom under the influence of magnetic field it 
tends to align parallel to the field and so exhibit paramag-
netic behaviour. But as a bulk material, it consists of sev-
eral iron atoms confined in a very small space. Therefore, 
the presence of multiple atoms leads to the formation of 
various domains and inside which the spin states are usu-
ally parallel to each other but not aligned parallel to the 
applied magnetic field or aligned in a single direction. 
Thus, when all the spin states in a given domain (and 
also all the domains) aligned in a single direction paral-
lel to the applied magnetic field it is called ferromagnetic 
state. If the spins are aligned anti-parallel to each other 
which in turn cancels itself with the overall net magnetic 
moment of zero units (or very close to zero), the states 
Fig. 1 A schematic representation of the development of MIONPs
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are known as anti-ferromagnetic states. On the other 
hand, if there is a presence of partial anti-parallel states in 
the given material, the overall magnetic moment will be 
less than the calculated value and such states are known 
as ferrimagnetic states [23, 24]. The ordering of spins in 
ferromagnetic, antiferromagnetic, ferrimagnetic and par-
amagnetic materials are presented in Fig. 2a.
In general, the number of magnetic domains in given 
magnetic material is directly proportional to the size of 
the material. Therefore, the reduction in size from bulk to 
as small as nanometre volume reduces the multidomain 
material to the single domain material (Fig.  2b). Thus, 
the presence of single domain confined to a nanometre 
volume which exhibit superparamagnetic behaviour with 
coercivity and remanence value close to zero. It is impor-
tant to know that the coercivity is the reverse magnetic 
field required to drive the magnetisation to zero while 
the remanence is the amount of magnetization remains 
after the applied magnetic field is switched off (i.e. at zero 
magnetic field). In other words, unlike the bulk ferro-
magnetic material, the superparamagnetic particle loses 
its magnetisation immediately after the applied magnetic 
field is switched off. This is due to the thermal energy 
overpowers the anisotropic energy barrier. For showing 
superparamagnetic behaviour the requirement for mini-
mum particle volume is  25kBT/K, where  kB is the Boltz-
mann constant, T is temperature and K is the anisotropic 
constant (K = −  1.1 × 105 erg/cm3 for  Fe3O4). Spherical 
 Fe3O4 nanoparticles with a particle size less than 26 nm 
exhibit superparamagnetic behaviour and their magnetic 
properties strongly depends on the methods of synthesis. 
The crystal structure affects coercivity in the order of its 
respective shape (spheres < cubes < octahedral). γ-Fe2O3 
particles of less than 30 nm size are superparamagnetic at 
room temperature [25].
Surface modifications by chemical treatments also have 
a strong affect on the magnetic properties of MIONPs 
[26]. Among the iron oxides,  Fe3O4 and γ-Fe2O3 are very 
commonly used for biomedical applications due to their 
stability, low toxicity and high saturation magnetization 
value. MIONPs with 10-30  nm particle size have more 
chemically active sites on its surface for bioconjuga-
tion and high saturation magnetization value for desired 
applications.
Synthetic methods of MIONPs
While various synthetic methods offer innovative 
approaches of controlling the nucleation and NPs growth 
process, efficient synthetic methods are in need to obtain 
desired size, structure and exact chemical composition of 
MIONPs. A lot of efforts have been taken to understand 
the mechanism of NPs formation in solutions via nuclea-
tion and growth [27]. Physical methods include metal 
evaporation by sputtering, ball milling and electrode 
deposition. These methods are advantageous since they 
allow mass production and high-purity nanomaterials 
but they do not offer a good control on the size and shape 
of the nanoparticle. Solution phase chemical methods 
offer effective ways to produce MIONPs because of their 
precise control over the composition, size and struc-
ture of the resultant materials. These chemical methods 
include co-precipitation, gas-phase deposition, sol–gel 
method, oxidation method, flow injection, microbials, 
herbal plants extract, thermal decomposition or reduc-
tion, hydrothermal synthesis, laser pyrolysis techniques 
and herbal extract mediated biosynthesis. In this section 
Table 1 Physical properties of important iron oxides [20–22]
Properties Magnetite Maghemite Hematite
Molecular formula Fe3O4 γ‑Fe2O3 α‑Fe2O3
Density (g/cm3) 5.18 4.87 5.26
Melting point (°C) 1583‑1597 – 1350
Hardness 5.5 5 6.5
Type of magnetism Ferrimagnetic Ferrimagnetic Weakly ferromagnetic or antiferromagnetic
Curie temperature (K) 850 820–986 956
The saturation magnetization (Ms) at 
300 K (A‑m2/kg)
92–100 60–80 0.3
Standard free energy of formation ΔGf
o 
(kJ/mol)
− 1012.6 − 711.1 − 742.7
Crystallographic system Cubic Cubic or tetragonal Rhombohedral, hexagonal
Structure type Inverse spinel Defect spinel Corundum
Space group Fd3 m P4332 (Cubic),
P41212 (tetragonal)
R3c (hexagonal)
Lattice parameter (nm) a = 0.8396 a = 0.83474 (cubic);
a = 0.8347, c = 2.501 (tetragonal)
a = 0.5034, c = 1.375 (hexagonal)
aRh = 0.5427, α = 55.3o (rhombohedral)
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Fig. 2 a The arrangement of spins in different magnetic materials. b Magnetization behaviour of ferromagnetic materials and superparamagentic 
nanoparticles under the external magnetic field turned on and off
Table 2 Comparison of important synthetic methods used of MIONPs
Method Size distribution Shape Advantages Limitations Magnetic 
values 
(emu/g)
Co‑precipitation 3–100 nm with broad distri‑
bution
Spherical Affordable, rapid and can be 
easily scaled up to larger 
scale
High polydispersity index
and controlling shape and 
size of NPs is challenging
20–50
Microemulsion and 
reverse microemul‑
sions
4–15 nm with narrow distri‑
bution
Spherical or cubic Desired size of the nanoparti‑
cles can be obtained by 
adjusting the aqueous core 
droplet size
Difficult to remove sur‑
factants and only small 
amounts can be synthe‑
sized
> 30
Sonochemical 20–80 nm with broad distri‑
bution
Spherical Use of fewer reagents and 
minimal purification steps
Highly specific experimental 
device required
20–85
Polyol 10–50 nm with narrow 
distribution
Cubic Easy to control the size and 
shape of the
nanoparticles
High‑temperature required 50–80
Thermal decomposition 6–80 nm with broad distribu‑
tion
Spherical Ability to synthesize highly 
crystalline MIONPs in the 
presence of surfactants
High temperature is required 
for producing nanopar‑
ticles
65
Hydrothermal 2–40 nm with narrow distri‑
bution
Spherical or cubic The particle size can be con‑
trolled easily by regulating 
the rate of nucleation and 
grain growth
High temperature and pres‑
sure are required
56–72
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ahead, we briefly introduce some important synthetic 
methods of MIONPS suitable for biomedical and indus-
trial interest. Comparison of various synthetic methods 
of MIONPs parameters apt for biomedical and industrial 
applications are given in Table 2.
Co‑precipitation method
Co-precipitation is a simple and beneficial way to imple-
ment eco-friendly synthesis of MIONPs and it was first 
performed by Massart [28]. Figure  3 shows the prepa-
ration of  Fe3O4 by using of ferrous and ferric salts in a 
molar ratio of 1:2 in alkaline aqueous solution under 
inert atmosphere at 70  °C. The type of salts used (chlo-
rides, sulfates, nitrates), Fe(II)/Fe(III) ratio, temperature, 
pH and ionic strength influence the size, shape and com-
position of the MIONPs. With standardized synthesis 
conditions, this process leads to the formation of spheri-
cal particles that allows mass production and do not 
require the use of expensive materials. The two main rea-
sons that make the MIONPs derived from this method 
become widely applied in biomedical field are simple, 
consequential productivity and direct dispersion in water 
without further treatment. Despite the advantage of 
being fast, simple, economic, environment friendly and 
easily transposable on a large scale, this method results 
in polydispersed MIONPs and the process of controlling 
the particle size is laborious and time consuming [29].
Microemulsion and reverse microemulsion methods
Microemulsions act as nanoreactors to synthesise super-
paramagnetic nanoparticles using thermodynamically 
stable isotropic dispersion of two immiscible liquids and 
stabilized by a surfactant molecule [30]. This process 
allows the control of the particle radius by exploiting the 
size of the reactors and the quantity of precursors avail-
able in each emulsion [7]. Different anionic, cationic and 
neutral surfactants are used, such as sodium dioctylsul-
phosuccinate, cetyltrimethylammonium bromide [31], 
sodium dodecylsulphate and polyethoxylates (Tween) 
for significant effects [32]. These surfactants allow con-
trol over the particle size by limiting the phenomena of 
crystalline growth and agglomeration of the nanoparti-
cles [7].
Figure  4 shows water-in-oil microemulsions where 
micro droplets of aqueous phase (below 50 nm) are sur-
rounded by a surfactant monolayer. In this method, two 
identical water-in-oil microemulsions containing the 
desired reactants were mixed to obtain the desired par-
ticle. By mixing both microemulsions, interchange reac-
tants occurs by continuous collision, coalesce, break 
again and finally ends in the formation of precipitate 
within micelles. The precipitate can be extracted upon 
addition of ethanol or acetone to the microemulsions 
either by filtration or by centrifugation [25, 33]. Even 
though varieties of MIONPs (spheroids, tubes or oblong 
Fig. 3 Schematic illustration of co‑precipitation synthetic method of MIONPs
Fig. 4 Schematic illustration of microemulsion method of MIONPs synthesis
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cross-sectioned nanoparticles) were synthesized by this 
method, yet it suffers from wide range of particle size and 
shape. In addition to that, this method offers low yield 
compared to co-precipitation [25, 33].
Sonochemical method
Decomposition of the iron precursors by thermolysis 
or sonolysis can also lead to the formation of iron oxide 
nanoparticles through sonochemistry. Organometallic 
precursors lead to amorphous, porous, agglomerated and 
small sized nanoparticles. The chemical effects of ultra-
sound arise from nonlinear acoustic phenomena, mainly 
acoustic cavitations such as the formation, growth and 
implosive collapse of bubbles in liquid [34]. Suslick et al. 
prepared nanoscopic amorphous iron powders using son-
ochemical methodology by taking iron carbonyl in decane 
[35]. These powders get fused and crystallized when 
heated above 300 °C. Figure 5 shows the sonication of iron 
carbonyl in the presence of a polyvinylpyrolidone (PVP) 
stabilizer which produces well-dispersed iron nanopar-
ticles. Surfactants, namely octadecyltrichlorosilane and 
oleic acid, or synthetic and natural polymers namely poly-
vinyl alcohol and chitosan can be added during or after 
sonication. The hydrodynamic diameter of the coated 
spherical MIONPs was 15 nm, ensuring the formation of 
good stable dispersion of nanoparticles [36, 37].
The very high temperature hot spot generated by the 
rapid collapse of sonically generated cavities allows for the 
conversion of ferrous penta carbonyl salts into MIONPs [8]. 
Ferrous acetate in deoxygenated water gives 10  nm sized 
 Fe3O4 particles by this method. The main advantages of this 
method are the use of few reagents and lesser purification 
steps [38, 39]. However, a modern experimental setup is 
required. The particle size can be controlled by altering the 
metal precursor or by changing the temperature.
Reduction or polyol method
High-quality MIONPs are often synthesised by the 
reduction of different stable metal precursors such as 
oxides, nitrates, chlorides, acetates and acetyl acetonates 
in the presence of polyols as the medium. Polyols often 
function as reducing agent, solvent, stabilizing agents and 
to prevent interparticle aggregation [3, 40]. Figure 6 illus-
trates the polyol solution containing an iron precursor 
heated in the range of 210–220 °C, which in turn results 
in nucleation and growth. It subsequently decreased the 
rate of oxidation and easy dispersion in polar solvents 
[41]. Higher temperature favours monodispersed  Fe3O4 
nanoparticles with higher crystallinity and magnetiza-
tion. The size and yield of MIONPs vary depending upon 
the type of polyols and ferrous salts, reduction potential 
of the polyols, ferrous and hydroxyl ion concentration 
and temperature. Polyols function not only as a solvent 
and a reducing agent, and also as a surfactant that lim-
its agglomeration [34, 40, 41]. The benefit of this method 
is easy to control the experimental conditions and to 
scale-up.
Thermal decomposition method
The coprecipitation and sonochemical methods men-
tioned above have several intrinsic draw-backs which 
include difficulty in producing highly uniform sized 
MIONPs, relatively low degree of crystallinity [42]. 
Thermal decomposition is a popular method used in 
industries to synthesise narrow sized MIONPs. In this 
method, the precursor containing surfactant solution 
is injected into a solvent at high temperature which in 
Fig. 5 Schematic representation of sonochemical synthesis of MIONPs
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turn decomposes the iron precursor in the presence of 
surfactant that will coat and stabilize the formation of 
MIONPs. By thermal decomposition method, highly 
mono dispersed MIONPs in a large scale can be synthe-
sised using suitable iron precursors (iron acetylacetonate, 
iron cupferron, iron oleate and iron pentacarbonyl etc.,) 
in a hot surfactant solution [43]. For mass production 
of MIONPs, ferrous and ferric fatty acid complexes are 
mainly used due to its cost-effective, non-toxic and easy 
to scale up. The MIONPs synthesised by thermal decom-
position method have high crystallinity with uniform size 
distribution led to the production of metallic nanocrys-
tals and semiconductors.
Hydrothermal method
Hydrothermal synthesis of  Fe3O4 nanoparticles in aque-
ous media are carried out in autoclaves/reactors at high 
temperature and pressure (above 200 °C and 13,790 kPa) 
[44–49]. Rapid nucleation and faster growth occurs at 
high temperature and it leads to formation of MIONPs 
(Fig. 7).
Two different routes were adopted for achieving 
MIONPs under hydrothermal conditions: (i) hydroly-
sis and oxidation and (ii) neutralization of mixed metal 
hydroxides [5]. The above two methods are similar, but 
differs in the use of pure ferrous salts in the former and 
the mixtures of ferrous and ferric salts in the later. This 
method makes it possible to control the geometry of the 
MIONPs by optimizing the conditions such as the reac-
tion time, temperature, solvent, concentration and stoi-
chiometry of reactants [45].
It was reported that the particle size of  Fe3O4 was 
influenced by water content and reaction time. When 
the water content was higher it leads to formation of 
MIONPs of larger size. Reaction temperature is also 
one of the factors affecting the size of MIONPs. It was 
observed that the particle size of MIONPs is controlled 
through nucleation rate and grain growth. Higher tem-
perature favours to rapid nucleation than grain growth 
and leads to formation of MIONPs of decreased size. The 
crystals formed by hydrothermal treatment are generally 
narrow sized with high purity and density. They do not 
aggregate due to the presence of stabilizing agents [44–
48]. Cai et al. synthesized polyethyleneimine (PEI) coated 
 Fe3O4 nanoparticles via a one-pot hydrothermal method 
using PEI as stabilizer [46]. Li et al. discussed the recent 
advances in hydrothermal synthesis of MIONPs, the vari-
ous aspects of the synthetic method and its functionali-
zation for biomedical applications like MR or dual-mode 
MR/CT imaging applications in particular [48].
Fig. 6 Schematic illustration of polyol synthesis of MIONPs
Fig. 7 Schematic illustration of hydrothermal synthesis of MIONPs
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Cytotoxicity
Various studies indicate that a dose level of iron 
upto100  µg/mL results in nontoxic effects. The toxic-
ity is due to high dosage of iron. It is already known that 
iron, apart from its catalytic action is also involved in the 
generation of free radicals, which cause peroxidation of 
membrane lipids, nucleic acid modification and protein 
oxidation [50–52]. Cytotoxicity occurs in both in  vitro 
and in vivo conditions. MIONPs offer a large surface area 
that contributes to the production of free radicals. In vivo 
toxicity is often caused by free radicals of MIONPs such 
as superoxide anion, nonradical hydrogen peroxide and 
hydroxyl radicals [53, 54].
MIONPs employed in biomedical applications such as 
targeted drug delivery to specific organs or tissues and 
usage of high concentration would consequently lead to 
its accumulation in the specific tissues or organs [55]. 
High levels of iron concentration in the tissues lead to 
imbalance in homeostasis causing undesired abnormal 
cellular responses such as oxidative stress, DNA dam-
age and inflammatory responses which also induced 
carcinogenesis [56–60]. Excessive concentration of iron 
causes liver cancer, in particular. Nanoparticles have an 
impact on the cell’s metabolic activity, proliferation, cell 
membrane integrity and apoptosis. Cytotoxicity of the 
nanoparticles is greatly minimized by appropriate choice 
of surface coating, size and shape of MIONPs. The nano-
particles can be spherical, rod-shaped, nanoworms and 
as magnetic beads. The extent of biocompatibility varies 
with different shapes and surface modifications [61]. The 
type of materials chosen for coating MIONPs and the 
products released upon their hydrolysis essentially deter-
mines their cytotoxic nature [62].
Surface coating of MIONPs with silica reduces its 
toxicity in live cells. Derivatives of dextran, polyethyl-
ene glycol (PEG), polyethyleneoxide (PEO), poloxamers 
and polyoxamines can also be used for surface coating. 
Nanoparticles coated with PEG decreases the chance of 
nonspecific uptake by macrophages [63]. Non-coated 
MIONPs carrying negative charge lead to protein dena-
turation when binding to serum proteins in the culture 
medium. There are also circumstances wherein vital 
nutrients and proteins required for cellular activities bind 
onto the non-coated MIONPs and severely affecting cel-
lular activities like cell growth and viability [64]. Thus, 
surface coating aids in developing a hydrophilic nature in 
iron oxide nanoparticles implying better biocompatibil-
ity [65]. Without a doubt, cytotoxicity of MIONPs can be 
widely kept under control with appropriate surface modi-
fications and coatings.
Most of the nanomaterials and wastes, which include 
nanoparticles and their by-products, will end-up in sur-
face waters consequently enter into aquatic systems with 
unknown potential risks to biota. The properties which 
represent MIONPs useful for the environmental reme-
diation, in particular their small size and high redox reac-
tivity, the same make them potentially harmful to biota 
[54] where the adverse effects of nanoparticles in organ-
isms remains unknown [2]. Chemical, physical, metabolic 
transformation and interaction with macromolecules 
will alter the fate, transport and toxicity of MIONPs [66]. 
Under natural conditions, while  Fe0 is reduced faster to 
iron oxides/hydroxides, it can significantly minimize the 
risk to organisms due to less cytotoxicity [67]. Mean-
while, the degree and volume of corrosion product leads 
to increase in the size of MIONPs [68]. Surface modifica-
tions of MIONPs may influence physiochemical proper-
ties of NP and might increase risk to biota. It is always 
essential to investigate both the core and the coating 
materials in combination and independent of each other. 
On the laboratory scale, applications of MIONPs for 
remediation have already proved their efficiency [69]. 
Although effects of their end products and resultant 
byproducts have not been fully investigated, there is need 
of insight into the long-term functional studies, which 
includes persistency and migration of MIONP in envi-
ronments [70].
Surface modification and stabilization
MIONPs synthesized by various methods require a sur-
face modification to achieve biocompatibility and long-
standing stability especially in biological media. MIONPs 
when left with a bare surface tend to agglomerate under 
the action of van der Waals forces, high surface energy 
and attractive magnetic forces existing among the parti-
cles. Stability and specificity are crucial for any applica-
tion of MIONPs. Various natural and synthetic polymers, 
organic and inorganic materials are currently employed 
as stabilizing matrices. Figure 8 presents the various nat-
ural and synthetic polymer, organic and inorganic mate-
rials used for stabilization of MIONPs [21, 63, 71, 72]. 
Size and properties of surface modifying agents used to 
modify the MIONPs surface play a key. Small sized mol-
ecules favour uniform surface coverage. The challenge 
is to create a sufficiently strong repelling power within 
the nanoparticles and decrease the interfacial tension 
of the system in order to obtain stable particles [34]. It 
could be addressed by coating the particles with repelling 
hydrophobic surfactants. Ligand interchange and encap-
sulation methods with amphiphilic polymers have been 
engaged to produce water-dispersible and biocompatible 
MIONPs. Tables 3, 4 and 5 briefly shows the properties, 
structure and applications of important polymers, and 
inorganic materials used for the stabilization of MIONPS.
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Natural and synthetic polymers
Electrostatic or steric repulsion can be used to prevent 
aggregation, disperse nanoparticles and preserve them 
in a steady colloidal state. The finest well-known example 
for such a system is the ferrofluid, invented by Papell in 
1965 [25, 73]. The most important measures to improvise 
the stability of ferrofluids are the regulation of surface 
charges by the use of specific polymers [25]. The poly-
meric shell can be manipulated with functional groups 
such as terminal amine or carboxyl moieties at the nan-
oparticle surface for further conjugation with bioactive 
molecules to target ligands and for other specific applica-
tions with multifunctional MIONPs [5].
A significant number of natural and synthetic biode-
gradable polymers are used (Tables  3 and 4), such as 
dextran [74], chitosan [75, 76], pullulan [77], human 
serum albumin [78], dendrimer [79, 80], polyaspar-
tate [81], polysaccharides [82], gelatin [83], starch [84], 
alginate [85], polyethyleneimine [86, 87], poly(acrylic 
acid) [88], Polyethylene glycol [89], poly(d,l-lactide) 
(PLA) [90–92], PEG-poly(aspartic acid) [93], poly(PEG 
monomethacrylate) [94], PLA-PEG [95, 96], poly(d,l 
lactide-co-glycolide) (PLGA) [97, 98], poly(alkyl 
cyanoacrylate) (PACA) [99, 100], chitosan-l-glutami-
cacid [101], poly(ε-caprolactone) (PCL) [102, 103] and 
non-biodegradable polymers like ethylcellulose [104, 
105] and polystyrene [106] for surface modifications. 
Surface modification of the particles with PEG is suit-
able for biomedical applications such as drug delivery 
due to its hydrophilic surfaces and prolonged rate of 
circulation in the blood stream. Surface coating with 
polystyrene on the other hand renders thermal sensitiv-
ity to the nanoparticles.
Fig. 8 Important surface modification materials for MIONPs
Table 3 Properties and applications of important natural polymers used to ensure stabilization of MIONPs
Name Nature and source Characteristics Applications
Alginate Anionic polymer obtained from brown sea‑
weed
Biocompatible
Low cost and less toxicity
Addition of divalent cations result in mild 
gelation leads to biomedical applica‑
tions
Used in
Delivery of low molecular weight drugs and 
proteins
Wound dressing
Tissue and bone regeneration
Transplantation of stem cells
Chitosan Cationic linear polymer derived from partial 
deacetylation of chitin
Biocompatible and biodegradable
Low allergenicity
Non‑toxic
Non‑viral gene delivery system
Obesity and age‑related disease treatment
Wound healing
Dry mouth syndrome treatment
Water treatment
Dextran Water‑soluble polysaccharide consists of 
mainly α‑1,6‑glycosides and rarely with α‑1,3 
branches obtained from bacteria
Biocompatible and biodegradable
Optimum polar interactions
Low cost and simple alternation
Colloidal solution is get stabilized by dextran 
and also helps in increasing circulation 
time in blood
Pullulan Water‑soluble polysaccharide comprising of 
linear chains of d‑glycopyranosyl units from 
fungus Aureobasidium pullulans
Adhesive ability
Boost nanoparticle colloidal stability
Accelerated biocompatibility
Targeted drug delivery along with excellent 
cytotoxic outcome
Transmucosal protein delivery
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Table 4 Structure, properties and applications of important synthetic polymers used to stabilize MIONPs
Name Structure Characteristics and applications
Polyethylene glycol (PEG)
O
H O
H
n
Surface shielding
Boost blood circulation
Solubility in buffer
Decrease charge‑based interactions
Polyvinyl alcohol (PVA)
OH
n
Backbone chain of carbon with hydroxyl group strengthen the hydrophilic and 
dispersion capacity in bio fluids
Prevent nanoparticle self‑aggregation
Polyethyleneimine (PEI)
NH
n
Non toxicity results in efficient gene delivery system
Branched PEI consists of primary, secondary and tertiary amino group results in 
transfection applications attributed by its high buffering capacity
Polyacrylic acid (PAA) O OH
n
Cell viability and high stability
Non‑aggregated dispersed state makes excellent protectant in drug delivery 
systems especially for ophthalmic and buccal
Poly(methyl methacrylate) (PMMA)
n
CH3
O O
CH3
Hindrance towards chemical hydrolysis
Flexible and biocompatible
Entangle hydrophobic drugs
Poly(alkyl cyanoacrylate) (PACC)
n
CN
ORO
Biodegradable
Easy preparation of nanoparticles in aqueous media
Targeted drug delivery in brain by diffuse across tumour cell membrane
Table 5 List of important inorganic materials used to ensure stabilization of MIONPs
Matrices Characteristics and applications
Silica Very stable and easily dispersed in solution
Stable at wide range of pH
Easy to attach several biomolecules, drug, fluorophores, quantum 
dots, dyes and ligands
Inert and biocompatible
Prevent aggregation of particles
Gold and silver Protect MIONPs from low pH corrosion
Offer extra optical properties
Gold‑silver chemistry facilitate easy conjugation with other molecules
Several applications in drug delivery
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Organic materials
Organic materials are often employed for the passivation 
of the nanoparticle surface, either during or after the syn-
thetic procedure, to avoid agglomeration and the prop-
erties of organic molecules can be exploited for different 
applications. MIONPs with functionalized surface offer 
the basic magnetic characteristics along with retention 
of good biocompatibility and biodegradability. Their sur-
face can be functionalized with reactive groups such as 
carboxyl, amine, hydroxyl, aldehyde that eventually can 
be used to bind to DNA and proteins such as antibodies, 
enzymes. Modifying MIONPs with dihexadecylphospho-
nic acid, dodecylphosphonic acid, hexadecylphosphonic 
acid, octadecanephosphonic acid, oleic acid, lauric acid, 
stearic acid, etc. can aid in stabilizing the nanoparticles in 
organic solvents [107–110]. Thermostability can be con-
ferred to MIONPs by attaching alkyl phosphonates and 
phosphates.
Inorganic materials
Surface modifications on MIONPs are also accomplished 
with inorganic compounds. It significantly increases 
the anti-oxidant properties of naked MIONPs for wider 
application scope. The functional coating with inorganic 
materials like silica, metal, non-metal, metal oxides and 
sulfides enable their use in catalysis, bio-labelling and 
bio-separation. Modified composite MIONPs retain the 
properties of both the inorganic material and iron oxide 
magnetism.
Inorganic materials like silica [111], gold [112], alu-
mina, also promotes stability in aqueous dispersion and 
offers a convenient platform for functionalization of the 
MIONPs for various applications. Chemical stability over 
broad pH range and biocompatibility is well achieved 
with silica coating to obtain stable ferrofluids.
Biomolecules and other such entities are crucial for 
targeted action and attachment of the desired moieties 
can be accomplished with ease by coating the particle 
surface with gold or silica. Silica outweighs other mate-
rials for coating the particles due to its silanol groups 
which in turn effectively reacts with coupling agents and 
offers classic support to suitable and desired molecules 
like proteins, ligands and antibodies on the surface via 
covalent bonding (Table 5). Jingchao Li et al. hydrother-
mally synthesized hyaluronic acid modified  Fe3O4-Au 
nanoparticles for tri-mode (MR/CT/thermal) imaging 
and photothermal therapy for cancer. First, the synthe-
sized  Fe3O4-Ag seeds are deposited with Au shells that 
can be modified with PEI via Au–S bond. Likewise, the 
PEI mediated reaction can be used for hyaluronic acid 
conjugation onto the surface of the nanoparticles [113]. 
Yong Hu et al. reported a unique multifunctional nano-
platform based on folic acid (FA)—modified  Fe3O4-Au 
nanoparticles. The PEI-coated  Fe3O4-Au nanoparticles 
were sequentially conjugated with FA through a polyeth-
ylene glycol (PEG) spacer via the PEI amine-enabled con-
jugation chemistry [114].
Applications of MIONPs
Nanometer sized MNPs are used in biomedical applica-
tions (Fig.  9) such as drug delivery, biosensors, biomo-
lecular separation, purification and cell labelling due to 
their strong magnetic properties [115–123]. Addition of 
nano receptors to the surface aids in targeting the essen-
tial pharmacological agents to the specifically desired 
areas of the human body. These receptors are designed to 
specifically recognize the target tissues for binding and to 
consequently release the drug molecules.
MIONPs were preferably chosen for biomedical appli-
cations due to its convenient synthetic methods, low 
toxicity and high saturation magnetization [124]. Sur-
face modifications of MIONPs are mandatory require-
ments that are heteronomous on the type of NP core 
and the aspired applications. Non-coated iron oxide NPs 
will have different effects on the cells of the body. Con-
jugation of biomolecules on the surface of nanoparticles 
is made possible via hydrogen, covalent, or ionic bonds. 
Surface modifications have an impact on its magnetiza-
tion, particle size, solubility and agglomeration in dif-
ferent solvents. Surface modification aims in attaining 
hydrophilic, hydrophobic, conductive and anti-corrosive 
properties in the NP. Widely used nano materials for sur-
face coating are  SiO2,  TiO2,  Al2O3,  Fe2O3, nano-alumin-
ium, nano-titanium. MNPs are exploited for theragnostic 
applications inclusive of visualization of the desired bio 
species, guiding into preferred sites using a magnetic 
field and heating in order to trigger drug release or to 
produce hyperthermia of desired tissues [12, 122–125].
Bio‑sensing
Nanomaterials have an appeal for being used as bio-
sensors due to their high catalytic efficiency, adsorp-
tion ability, large surface-to-volume ratio for surface 
reaction and for the ease of immobilizing suitable mol-
ecules for bio-sensing such as for glucose detection. 
MIONPs can be used as a biosensor for its stable cata-
lytic activity toward several substrates of biological or 
environmental consequence, such as soluble oxygen, 
trichloroacetic acid, nitrite and hydrogen peroxide 
[126]. The principle behind the detection involves the 
oxidation of glucose by glucose oxidase to yield perox-
ide which further oxidises ABTS (2,2′-azino-bis(3-eth-
ylbenzothiazoline-6-sulphonic acid)) in the presence of 
peroxidase. This chromogenic reaction aids in detect-
ing glucose. The release of hydrogen peroxide during 
glucose oxidation is used to indirectly detect glucose. 
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MIONPs were found to have the functions of peroxi-
dise when they were attached with horseradish per-
oxidase [127]. Large scale production of peroxidase 
enzymes are hard due to the possibilities of proteolytic 
degradation whereas such problems are not encoun-
tered for yielding higher mass of MIONPs. The choice 
of MIONPs for immobilizing glucose oxidase is attrib-
uted to its low toxicity, superparamagnetic nature and 
biocompatibility along with prolonged stability [126, 
128]. MIONPs are appreciated for bio-sensing due to 
its high sensitivity and rapid result. An essential aspect 
of its catalytic ability depends on its binding with the 
substrate. Binding affinity with the substrate can be 
regulated by manipulating the charge and its strength 
on the surface of MIONPs. This can be achieved by 
using different surface-active materials. Various sur-
face modifications with citrate and g lycine, polylysine 
and poly(ethyleneimine) or carboxymethyl dextran and 
heparin could be done for glucose detection.
Drug delivery
Nanoparticles are being preferred in the drug delivery 
action due to their efficiency in targeting drugs to the 
desired diseased cells and tissues [129, 130]. The nano-
particle surface contains a ligand along with the poly-
mer coating which binds with the specific receptor on 
the target. The entry of drug loaded nanoparticles into 
the aspired destination highly depends on the ligand-
receptor match. The nanoparticles are denied entry into 
the cell when the ligand-receptor match fails. When this 
comes to treating diseases, it has the additional advan-
tage of prolonging the existence of drugs inside the bio-
logical system with parallel benefits of decreasing the 
frequency of painful injections.
Fig. 9 Important biomedical applications of MIONPs
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MIONPs are attributed for their distinctive character-
istics and potential to perform at the cellular level with 
high specificity and low toxicity [131]. The toxicity is fur-
ther reduced by concealing the drugs within the designed 
nanocarrier [127, 132]. Other prospective advantages 
include the achievement of desired drug concentration at 
the target site with low quantity of loaded drug on the car-
rier and reduced concentration of drug at the non-target 
sites [125, 133]. Drugs can be combined with MIONPs in 
several ways. They could be accumulated on the MIONP 
surface or trapped within the MIONP structure. They 
could also be attached with the functionalised moieties on 
the MIONP surface. Drugs are liberated at the target site 
by diffusion, dissolution, endocytosis [134, 135].
Cancer treatment
Chemotherapeutic strategies to treat cancer are mostly 
non-specific and leads to the destruction of many healthy 
cells along with the target tumour. MIONPs could be 
used as specific drug carriers to outstand such problems 
[136]. Various chemotherapeutic drugs like methotrex-
ate (MTX), doxorubicin (DOX), paclitaxel are conjugated 
with MIONPs to fight cancer [137–139]. Yu et al. synthe-
sised MIONPs coated with a negatively charged polymer 
to load the positively charged doxorubicin (DOX) with 
electrostatic interactions [140]. These MIONPs demon-
strated reduction in the tumour size when injected into 
mice with lung cancer. MIONPs can be used to treat can-
cer in various ways [141].
MIONPs are conjugated with monoclonal antibodies 
in cancer treatment. Cancer cells are distinguished from 
normal cells with increased number of epidermal growth 
factor receptors (EGFR) which actively binds to epider-
mal growth factors. These growth factors induce the 
ability of the cancer cells to increase in size, volume and 
promote cellular division. Monoclonal antibodies bind 
specifically to epidermal growth factor receptors block-
ing them to prevent their binding to EGF.
Hyperthermia for tumour therapy can be achieved 
with MIONPs. The effect of hyperthermia is produced 
when MIONPs act as an oscillating magnet under exter-
nal magnetic field followed by its conversion into heat to 
raise the temperature of tumour tissues and subsequent 
destruction of pathological cells. Specific absorption rate 
(SAR) determines the heat attained by the MIONPs. SAR 
defines the conversion of magnetic field to heat. SAR val-
ues for MIONPs are generally estimated with Neel and 
Brownian relaxation. Tumour cells are made inviable by 
exposing them to a temperature range of 41–45  °C for 
a time span of 30  min. Heat produced in the treatment 
is restricted to the specific tumour tissues pertaining to 
the property of MIONPs where heat is produced at the 
cost of hysteresis loss on exposure to high frequency of 
approximately 1 MHz.
MIONPs can be loaded with drugs and are guided to 
the desired target site with an external magnetic field 
with simultaneous tracking and bio distribution of nan-
oparticles proving them theragnostic [142]. MIONPs 
existing in conjugation with the required targeting moi-
eties fused with the application of an external magnetic 
field assure a very promising alternative for simultaneous 
imaging of inflammation and drug delivery to inflamma-
tory sites by maintaining an appropriate local concen-
tration with reduced overall dosage and side effects [12, 
143].
MIONPs can be manifested to carry specific drugs for 
the therapy. The choice of using MIONPs for deliver-
ing drugs within the human body is to increase the drug 
life and its protection from degradation by specific sur-
face modification of nanoparticles [144]. The extremely 
small sizes of MIONP succour them to penetrate through 
smaller capillaries and hence are captured by affected 
cells with ease. The drug employed for therapeutic pur-
pose can either be active or passive. Active drugs are 
targeted to the explicit sites of the system like tissues, 
organs, cells. Passive drugs are circulated throughout the 
biological system homogenously. These methods of drug 
circulation are implemented and favoured by the proper-
ties of the drug’s carrier. Circulation and distribution of 
drugs are efficiently controlled by external magnetic field. 
MNPs prove itself very efficient with their ability to cross 
various biological barriers like the blood brain barrier 
(BBB) and penetrate deep inside. MIONPs make it pos-
sible to efficiently deliver drugs to the brain tumour cells. 
MIONPs in the gene delivery system loads the therapeu-
tic genes for escorting them to the diseased sites to facili-
tate their shuttling across the target cell membranes and 
to ultimately release them intracellularly to accomplish 
their functions [142, 145, 146].
The sizes of MIONPs play a very crucial role in its bio-
logical elimination within the body. Particles with sizes 
more than 200  nm are usually filtered in the spleen. 
MIONPs around 100  nm are predominantly phagocy-
tosed by liver cells and hence MIONPs with large size 
have a short life period in the plasma [125]. The potency 
of this method highly depends on field strength, blood 
flow rate, thickness of tissues at the target site, etc. [147]. 
Small MIONPs remains in blood plasma evading the bio-
logical elimination and their superparamagnetic nature 
prevents agglomeration in the absence of external mag-
netic field [148]. The physical and chemical properties of 
MIONPs can be enhanced for utilization by additional 
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functionalization’s with amino group, various surfactants, 
polymer, silica or other organic compounds. The func-
tional groups existing on the surface coated polymer has 
the advantage to attain new properties or to enhance the 
existing properties of drugs.
Imaging
MIONPs also led its way in magnetic resonance imag-
ing (MRI) owing to quantitative data with superior 
spatial resolution and appreciable penetration into tis-
sues despite being harmless of the magnetic field [121, 
149–153]. The human body has a net magnetic moment 
of zero and exhibits a significant magnetic moment with 
the presence of an external magnetic field. MRI is done 
40 min after infusing MIONPs. MIONPs are later elimi-
nated from the system by immune cells through phago-
ctosis. MIONPs offer benefits like safety, high relaxivity 
and blood half-life. Vascular structures like cardiac cham-
bers, pulmonary arteries and aorta can be imaged with 
MRI. Thus, nanoparticles hold significant potential both 
for MRI and MRI-guided delivery (i.e., controlled drug or 
gene delivery) [121, 152, 153].
MIONPs for tumour imaging
The over expressed ligands on the surface of tumour 
cells serve as the target for imaging. αvβ3 integrin is 
found on the surface of many tumours in breast cancer, 
prostate cancer, ovarian cancer, glioblastoma, etc. αvβ3 
integrin plays an important role in metastasization and 
angiogenesis. A cyclic arginine–glycine–aspartic acid 
(cRGD) peptide sequences are designed to target integ-
rin’s [154–156]. MIONPs were functionalised with phos-
phonate PEG chains covalently linked with cRGD peptide 
sequence. These MIONPs were tested in vivo in tumour 
xenograft mice to check their efficacy in functioning as a 
contrast agent. MIONPs accumulated at the tumour sites 
after injection showed efficient and specific targeting of 
the tumour cells. MIONPs synthesised with Si–OH con-
taining co-polymer for the surface could also be used as a 
contrast agent for in vivo imaging of cancer cells.
MIONPs in MRI for stem cell tracking
Stem cells are undifferentiated mass of cells that have 
the marvellous potential of differentiating into different 
cell types. Their important properties are self-renewal 
and differentiation potential. Self-renewal results in the 
cell divisions to form daughter cells and the daughter 
cells mature into various types of cells with its capacity 
to differentiate. Sometimes loss of control over the pro-
liferation of embryonic stem cells may lead to tumour 
formation with inconsistent phenotype. MIONPs 
can be used to track these stem cells with the widely 
adopted existing imaging technique-MRI. Interaction 
of MIONPs with stem cells are very much depend-
ent on cell receptors, antibodies and the charge of cell 
membrane. Hence MIONP architecture combined with 
complementary target proteins, ligands have gained 
desirability over the past few decades in medical appli-
cations [157–160]. MIONPs can either be conjugated to 
the surface of stem cells or could be internalised [161]. 
Surface architecture and the size are altered to boost 
successful cellular uptake of MIONPs for non-invasive 
tracking of stem cells. MIONPs with low iron content 
favours by its low toxicity and the release of iron dur-
ing its breakdown has been studied to have insignificant 
toxicity and it’s the surface coating material that largely 
influences the cell. Cellular uptake of MIONP can be 
enhanced by the use of suitable polymer coating, trans-
fection agents or by linking the MIONP with monoclo-
nal antibodies [162–166].
MIONPs for brain tumour
Glioblastoma is a brain tumour that is hard to treat 
despite early detection due to its infiltrative nature caus-
ing recurring tumours in the diseased patients [167]. 
Current treatment including surgery, radiation and adju-
vant chemotherapy leaves residual tumour cells in the 
patients which eventually lead to their death [168, 169]. 
MIONPs can be used to image tumours via MRI by con-
jugating specific antibodies or peptides to target cancer 
cells [170, 171]. Blood brain barrier poses a major chal-
lenge to this treatment strategy. Intratumoural deliv-
ery of MIONPs favours its desired concentration at the 
tumour target with low toxicity and maximum hyper-
thermic effect in the tumours alone rather subjecting the 
entire brain to hyperthermia. Exposure of healthy tis-
sues to hyperthermia leads to various side effects [172]. 
Brain autopsies have confirmed the presence of MIONPs 
within tumour targets after implantation [173].
Oil recovery
Oil spills are generally caused by damaged tankers, 
destruction of oil pipelines, etc. It results in huge eco-
nomic lose and environmental damage that usually lasts 
for a span of several decades. Oil spills have a wide nega-
tive impact on birds, mammals, fishes and to the ecosys-
tem. The oil is found adsorbed on the rocks and the sand 
which offers unfavourable conditions for plant growth. 
The oil floating over the water destroys the underwater 
ecosystem and disrupts food chain. Birds and animals 
tend to ingest the oil which is poisonous to them. Even 
a small amount of oil is detrimental to birds. Oil stuck to 
the feathers of the birds hinders their flight and causes 
hypothermia. Adult fishes on exposure to oil suffer from 
altered respiration rates, fin erosion, enlarged liver and 
impaired reproductivity. The oil clogs the blowholes 
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of dolphins and whales causing hindrance for them to 
breathe and communicate. Oil spills are generally seques-
tered with floating barricades and are then removed 
through vacuum or by special absorbents [174]. Current 
treatment strategies have their share of limitations that 
includes low efficiency, high labour and toxicity, sinking 
of oil and the consequent damage to the marine eco-sys-
tem. Novel strategies are developed for oil recovery using 
nanotechnology for their higher efficiency in oil removal 
over a shot span of time and cost effectiveness [175, 176]. 
MIONPS coated with polysiloxance and collagen help in 
efficient oil recovery [177, 178]. Calcagnile et al. discov-
ered that MIONP bound to polyurethane foam make oil 
separation possible with efficient recovery and reusability 
[179]. Various studies have highlighted the prospective 
role of MIONPs in oil recovery. Due to its low toxicity 
and easy magnetic separation, MIONPs appears to be 
more functionally efficient than cobalt or nickel nano-
particles [25, 180]. MIONPs coated with superhydropho-
bic polyester material displayed selective adsorption of 
oil [181]. MIONPs functionalised with hydrothermally 
reduced graphene oxide (RGO) foam are used for oil 
adsorption and it could be easily separated with magnetic 
field. RGO foam is attributed as a fantastic sorbent for 
oil recovery due to its hydrophobicity, high surface area 
and easy recovery. It demonstrated a sorption capacity 
of 40 g oil/g foam [182]. Silicate clay could also be used 
to coat MIONP for enhancing oil spill treatments [183]. 
MIONPs synthesised with amphiphilic organic domains 
on their surface could be used for seizing hydrocar-
bons in the crude oil. The contaminants were removed 
at a ratio of 10  mg of oil per 1  mg of MIONPs and the 
MIONPs were withdrawn by external magnetic field. Zhu 
et  al. demonstrated that MIONPs coated with vinyl tri-
ethoxysilane manifests efficient oil sorption [177]. These 
materials showed selective adsorption to hydrophobic 
pollutants in the contaminated environment. Amphiphi-
lic materials have the advantage of recovering oil with dif-
ferent densities [184]. Mesoporous silica-coated MIONPs 
are an amphiphilic recovery agent that has shown high 
adsorption efficiency of hydrocarbons in the polluted 
aqueous environment. The hydrophobic MIONPs could 
be made oil-adsorbing by coating the particles with pol-
ytetrafluoroethylene through particle deposition tech-
nique. It resulted in low cost rapid oil adsorption, good 
magnetic response and the particles floated on water due 
to their low weight enabling easy removal. The synthesis 
and reusability need to be focused to incorporate more 
novelty to this strategy [185].
Catalysis
MIONPs are preferred over other metal catalysts for 
their non-toxic, ubiquitous and cost effectiveness. They 
have indeed become increasingly appealing in the field 
of catalysis over the last decade as they combine their 
fascinatingly reactive properties with an easy environ-
mental benign mode of recovery [186]. The separation 
of MIONPs indulges them in the prominent industrial 
applications [187]. It could be used bare [188, 189] or by 
plating it with an appropriate metal that is catalytically 
active [190, 191]. MIONPs are well renowned for its easy 
recovery, ease of handling and catalytic activity for vari-
ous applications. MIONPs can be used as a catalyst for 
anti-Markovnikov conversion of alkenes to alkynes by 
the addition of thiols. It could also be used as a catalyst 
for thia-Michael addition, substitution reaction and thiol 
esters synthesis. The addition reaction of thiophenol with 
styrene in the presence of 4  mol% MIONPs as catalysts 
resulted in anti-Markovnikov products with a yield range 
of 95–100%. MIONPs have the catalytic ability to alter 
the rate of the reaction in an anti-Markovnikov fashion 
and the catalytic activity was found to be restored for 
eight successive runs after followed by repeated washing. 
No major alterations in the morphology or distortions in 
the structure were observed due to repeated washing and 
hence it serves as an effective catalyst [192–196].
MIONPs synthesised in  situ between the reaction of 
hydrazine monohydrate and iron salt in methanol at high 
temperature have proved to be effective catalysts in spe-
cifically reducing aromatic nitro groups into anilines with 
the aid of a reducing agent like hydrazine [197]. MIONPs 
have also involved in methylene blue degradation. Meth-
ylene blue degradation accomplished by sodium borohy-
dride was found to have an escalated rate of degradation 
reaction after the addition of MIONPs [198].
Water remediation
Water being one of the most imperative entities needs 
to be remediated and preserved for beneficial global 
sake. There are beneficial elements in water which when 
exceeds in concentration can be extremely toxic. Higher 
concentration of fluoride intake will cause fluorosis. This 
chronic condition can be prevented by defluoridation. 
MIONPs coated with hydrotalcite or chitosan [199] has 
been discovered to withdraw high amounts of fluoride 
from drinking water via ion exchange mechanisms and 
electrostatic adsorption where the negatively charged flu-
oride gets attracted to the positively charged aluminium, 
magnesium and ferric ions on the surface of the nano-
particle. Studies revealed that large amount of fluoride 
were adsorbed at acidic conditions whereas MIONPs 
were able to remove the least amount of fluoride at alka-
line conditions. So desorption of the adsorbed fluoride 
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on MIONPs are usually removed in alkaline conditions. 
They can also be used to specifically eliminate trace ele-
ments to regulate remediation [19]. MIONPs synthesised 
by the reduction of borohydride or polyphenol with Pd 
and Ni fabrication have been successful in rapid and 
efficient reduction of unwanted pollutants [199–201]. 
Polychlorinated biphenyls (PCBs) can be removed from 
ground water using polyvinylidene fluoride (PVDF) 
membrane functionalised with polyacrylic acid (PAA) 
coated MIONPs. PCBs are removed by combined oxida-
tive and reductive degradation [202]. In the case of sele-
nium, selenium is reduced to selenate (VI), and selenite 
(IV) to elemental selenium and selenide by MIONPs 
[200, 203, 204]. Arsenic richly found in sediments and 
rocks are highly likely to be found in drinking water and 
its consumption deteriorates living beings. MIONPs inte-
grated with different materials have shown large potential 
in removing heavy and toxic metals from drinking water 
[19, 205–207].
Conclusions and perspectives
As the perspective of the implication of MIONPs in bio-
medical and industrial research has been increasingly 
witnessed, the main motive is to enlighten the efficient 
MIONP synthetic methods with minimal hazards, at 
the same time to alleviate the efficacy issues of MIONPs 
owing to their cytotoxicity. Such cytotoxic effects can be 
subsided and kept under control through proper surface 
modifications, using polymers, silica coating and several 
other available functionalization strategies discussed 
earlier. MIONPs are eco-friendly and represent a higher 
performance than other types of nanoparticles due to 
their chemical stability and biocompatibility with cost-
effectiveness. Unlike the MIONPs, the cobalt and nickel 
nanoparticles are susceptible to oxidation, as they exhibit 
toxicity towards biological entities, and therefore not 
suitable for biomedical applications.
Silica coating, apart from being an efficient surface 
modification tool which reduces toxicity by minimis-
ing particle aggregation also provides stability and aids 
biocompatibility. Bigger particles possess the added 
advantage of their ease in separation, despite their limita-
tions such as low magnetic moment and particle aggre-
gation. On the other hand, small sized particles have a 
higher magnetic moment and aggregate less, however 
posing problems on their separation thus complicating 
the entire process. In order to strike a balance between 
these two approaches, incorporation of small sized 
MIONPs into clusters seem to be the most efficient way 
for increasing the magnetic moments per carrier together 
with easy separation.
In the current research scenario, nanoparticles are the 
preferred candidates for drug delivery action due to their 
efficiency in targeting drugs to the diseased cells and tis-
sues. It can be advanced one step further by coupling var-
ious moieties responsive to suitable external stimuli such 
as temperature, light, etc. to improve the efficiency of 
targeted drug delivery and to allow programmed delivery 
of therapeutic agents. In order to attain uniform particles 
with desired charge, shape, size and magnetic moment, 
more efforts can be emphasised on optimizing the syn-
thetic methods. The efforts through this review also 
clearly paves a way for the efficient synthesis of MNPs, to 
overcome the several obstacles discussed hitherto. It pro-
vides further hints to exploit efficient synthetic methods, 
while keeping in mind the vital scope of MIONPs for bio-
logical and industrial applications.
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